United Therapeutics Management
Management criteria checks 2/4
United Therapeutics' CEO is Martine Rothblatt, appointed in Jan 1996, has a tenure of 30.25 years. total yearly compensation is $23.01M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 1.55% of the company’s shares, worth $389.87M. The average tenure of the management team and the board of directors is 21.8 years and 23.5 years respectively.
Key information
Martine Rothblatt
Chief executive officer
US$23.0m
Total compensation
| CEO salary percentage | 6.57% |
| CEO tenure | 30.3yrs |
| CEO ownership | 1.6% |
| Management average tenure | 21.8yrs |
| Board average tenure | 23.5yrs |
Recent management updates
Recent updates
The Organ Manufacturing Frontier: More Than Just a Pharma Play?
As of February 2026, United Therapeutics has solidified its position as a dominant force in the pulmonary arterial hypertension (PAH) market. The company’s "Tyvaso" franchise has seen a 22% year-over-year surge in adoption, particularly as the DPI (Dry Powder Inhaler) version takes market share from more invasive delivery methods.United Therapeutics: Growing Company With Great Franchise In Pulmonary Diseases
Nov 21United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement
Sep 03
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Jul 22Does United Therapeutics (NASDAQ:UTHR) Have A Healthy Balance Sheet?
May 11Investors Aren't Buying United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Apr 23United Therapeutics: A Unique Business With High Margins And Expansion Potential
Feb 25United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14
Innovative Biotech Products Pave The Way For A Future Revenue Surge And Market Leadership
Advancements in treatments for pulmonary hypertension and fibrosis, and pioneering Xenotransplantation products, promise to lead market growth and address unmet medical needs.United Therapeutics: Economics Support Compounding Ability
Aug 20United Therapeutics: Exciting Company With A Big Problem
Jun 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$1b |
| Sep 30 2025 | n/a | n/a | US$1b |
| Jun 30 2025 | n/a | n/a | US$1b |
| Mar 31 2025 | n/a | n/a | US$1b |
| Dec 31 2024 | US$23m | US$2m | US$1b |
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
Compensation vs Market: Martine's total compensation ($USD23.01M) is above average for companies of similar size in the US market ($USD14.14M).
Compensation vs Earnings: Martine's compensation has increased by more than 20% in the past year.
CEO
Martine Rothblatt (70 yo)
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 30.3yrs | US$23.01m | 1.55% $ 389.9m | |
| President & COO | 9.8yrs | US$13.89m | 0.050% $ 12.5m | |
| CFO & Treasurer | 13.3yrs | US$9.16m | 0.043% $ 10.8m | |
| Executive VP | 30.3yrs | US$6.96m | 0.10% $ 25.9m | |
| Manager of Investor Relations | no data | no data | no data | |
| Associate Vice President of Human Resources | no data | no data | no data | |
| Executive Vice President of Product Development & Xenotransplantation | no data | no data | no data | |
| Senior VP & Chief Medical Officer | no data | no data | no data |
Experienced Management: UTHR's management team is seasoned and experienced (21.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 30.3yrs | US$23.01m | 1.55% $ 389.9m | |
| Independent Director | 24.3yrs | US$439.57k | 0.029% $ 7.3m | |
| Independent Director & Member of the Scientific Advisory Board | 23.6yrs | US$469.57k | 0.0086% $ 2.2m | |
| Member of the Scientific Advisory Board & Independent Director | 24.3yrs | US$438.48k | 0.0040% $ 1.0m | |
| Independent Vice Chairman & Lead Independent Director | 23.5yrs | US$514.57k | 0.0059% $ 1.5m | |
| Independent Director | 22.8yrs | US$500.28k | 0.0096% $ 2.4m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 24.3yrs | US$438.48k | 0.049% $ 12.4m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.8yrs | US$475.28k | 0.0097% $ 2.4m | |
| Independent Director | 17yrs | US$500.28k | 0.047% $ 11.8m | |
| Independent Director | 7.5yrs | US$469.57k | 0.012% $ 3.0m |
Experienced Board: UTHR's board of directors are seasoned and experienced ( 23.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/21 21:30 |
| End of Day Share Price | 2026/04/21 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
United Therapeutics Corporation is covered by 34 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |